RetinalGenix Technologies contracts LabCorp to support on DNA/RNA/GPS Pharmaco-Genetic Mapping platform

(Image Credit: AdobeStock)

RetinalGeniX has contracted LabCorp to support the rollout of the RetinalGeniX DNA/RNA/GPS Pharmaco-Genetic Mapping platform.

The program allows patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases. Through the collaboration, patients may visit any USA-based LabCorp location to have blood, tears, nasal secretions, and saliva collected and analyzed using proprietary algorithms developed by the RetinalGenix and DNA/RNA GPS analysis platform.

According to the company, these tests may correlate genetic and retinal biomarkers, ultimately seeking to establish a new standard for early detection of a wide range of health conditions. Patients may elect to have their data analyzed using specific algorithms developed by RetinalGenix, paired with DNA/RNA/GPS to correlate with current and future biomarkers found in the eye and the blood.

Larry Perich, DO, advisor for the DNA/RNA/GPS program, noted, “As the database of disease-associated biomarkers expands, we expect the value of these platforms for diagnosing both ocular and systemic diseases continues to grow, promising improved outcomes and more accessible care.”

The company specified that patients maintain full control of their health records, which remain anonymous and confidential.

RetinalGenix stated that high-resolution retinal imaging will be introduced as a value-added additional service at various locations in the near future. These innovations are designed to make screening more accessible, cost-effective, and capable of detecting disease earlier, according to the company.

Jerry Katzman, MD, CEO of RetinalGenix Technologies, noted that the company is currently working with regulators to establish CPT codes, which could further help lower healthcare costs and improve access to necessary evaluations.

Reference:

1. RetinalGenix Technologies contracts with LabCorp to support DNA/GPS platform for advanced genetic and retinal health screening. Published June 27, 2025. Accessed June 30, 2025. https://avttx.com/ashvattha-therapeutics-presents-positive-interim-phase-2-results-for-subcutaneous-migaldendranib-treatment-for-dme-and-wet-amd-at-2025-maculart-meeting/